A Phase II Open Label, Randomized Study Testing the Efficacy of Retifanlimab in Combination with Bevacizumab and Hypofractionated Radiotherapy in Patients with Recurrent GBM

This phase II trial tests how well retifanlimab with bevacizumab and hypofractionated radiotherapy, compared to bevacizumab and hypofractionated radiotherapy alone, works in treating patients with glioblastoma that has come back after a period of improvement (recurrent). A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as retifanlimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Giving retifanlimab with bevacizumab and hypofractionated radiotherapy may work better in treating patients with recurrent glioblastoma than bevacizumab and hypofractionated radiotherapy alone.

开始日期2024-10-02

申办/合作机构

National Cancer Institute

NCT06290622 / Withdrawn临床1期IIT

PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL Post Chimeric Antigen Receptor T-cEll Therapy fAilUre (PLATEAU Study)

This study is investigating the optimal dose and the advantage in combining investigational immunotherapy drugs known as Retifanlimab, INCAGN02385 and INCAGN02390 to improve the responses to CAR T-cell therapy. Additionally, the study will investigate that triple checkpoint blockade of PD-1, TIM-3 and LAG-3 molecules will overcome CAR T-cell therapy resistance in patients with suboptimal responses.

开始日期2024-08-30

申办/合作机构

The University of Alabama at Birmingham

NCT06389799 / Recruiting临床2期IIT

A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma

Dedifferentiated liposarcomas (DDLPS) are aggressive soft tissue sarcomas with no effective medical treatment options.
Immunotherapy with checkpoint inhibitors, so-called PD-1 inhibitors, have shown some effect in DDLPS in previous studies. Effect of immunotherapy can be improved by combining it with other types of tumor drugs. Medicines that inhibit signaling via the FGF receptor, so-called FGFR inhibitors, have shown a tumor-slowing effect in DDLPS in early studies. FGFR inhibitors can also induce changes that make the tumor more available to treatment with immunotherapy.
The study aims to investigate whether the combination of an FGFR inhibitor, pemigatinib, with a PD-1 inhibitor, retifanlimab can provide a tumor-slowing effect in patients with advanced DDLPS who have progressed on first-line treatment.

开始日期2024-06-20

申办/合作机构

Lund University Hospital

100 项与瑞弗利单抗相关的临床结果

登录后查看更多信息

100 项与瑞弗利单抗相关的转化医学

登录后查看更多信息

100 项与瑞弗利单抗相关的专利（医药）

登录后查看更多信息

项与瑞弗利单抗相关的文献（医药）

2024-12-31·mAbs

Antibodies to watch in 2024

Article

作者: Crescioli, Silvia ; Kaplon, Hélène ; Wang, Lin ; Reichert, Janice M. ; Visweswaraiah, Jyothsna ; Chenoweth, Alicia

The 'Antibodies to Watch' article series provides an annual summary of commercially sponsored monoclonal antibody therapeutics currently in late-stage clinical development, regulatory review, and those recently granted a first approval in any country. In this installment, we discuss key details for 16 antibody therapeutics granted a first approval in 2023, as of November 17 (lecanemab (Leqembi), rozanolixizumab (RYSTIGGO), pozelimab (VEOPOZ), mirikizumab (Omvoh), talquetamab (Talvey), elranatamab (Elrexfio), epcoritamab (EPKINLY), glofitamab (COLUMVI), retifanlimab (Zynyz), concizumab (Alhemo), lebrikizumab (EBGLYSS), tafolecimab (SINTBILO), narlumosbart (Jinlitai), zuberitamab (Enrexib), adebrelimab (Arelili), and divozilimab (Ivlizi)). We briefly review 26 product candidates for which marketing applications are under consideration in at least one country or region, and 23 investigational antibody therapeutics that are forecast to enter regulatory review by the end of 2024 based on company disclosures. These nearly 50 product candidates include numerous innovative bispecific antibodies, such as odronextamab, ivonescimab, linvoseltamab, zenocutuzumab, and erfonrilimab, and antibody-drug conjugates, such as trastuzumab botidotin, patritumab deruxtecan, datopotamab deruxtecan, and MRG002, as well as a mixture of two immunocytokines (bifikafusp alfa and onfekafusp alfa). We also discuss clinical phase transition and overall approval success rates for antibody therapeutics, which are crucial to the biopharmaceutical industry because these rates inform decisions about resource allocation. Our analyses indicate that these molecules have approval success rates in the range of 14-32%, with higher rates associated with antibodies developed for non-cancer indications. Overall, our data suggest that antibody therapeutic development efforts by the biopharmaceutical industry are robust and increasingly successful.

2024-07-01·ESMO Open

Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies

Article

作者: Tian, C ; Subbiah, V ; Papadopoulos, K P ; Saleh, M ; Mettu, N B ; Morgensztern, D ; Veronese, M L ; Silverman, I M ; Barve, M ; Gutierrez, M ; Spanggaard, I ; Roychowdhury, S

BACKGROUND:

Pemigatinib is an oral, potent, selective fibroblast growth factor receptor (FGFR) 1-3 inhibitor. FIGHT-101, a three-part, open-label, first-in-human, phase I/II study (NCT02393248), evaluated pemigatinib in patients with advanced solid tumors. In parts 1 and 2, pemigatinib monotherapy had a manageable safety profile and antitumor activity in FGFR-altered tumors. Part 3 (pemigatinib combination therapies) results are presented here.

PATIENTS AND METHODS:

Patients received 9, 13.5, or 20 mg oral once-daily pemigatinib on continuous or intermittent schedules with gemcitabine and cisplatin (pemi/gem/cis), docetaxel (pemi/doc), trastuzumab (pemi/tras), pembrolizumab (pemi/pembro), or retifanlimab (pemi/reti) irrespective of whether the tumor was confirmed as FGFR altered. Primary endpoints were safety and pharmacodynamics. Secondary endpoints were investigator-assessed tumor objective response rates (ORRs) and pharmacokinetics (PK).

RESULTS:

Of 65 enrolled patients (pemi/gem/cis, n = 8; pemi/doc, n = 7; pemi/tras, n = 6; pemi/pembro, n = 26; pemi/reti, n = 18), all discontinued. Treatment-emergent adverse events (TEAEs) were generally consistent with individual drug AEs. Serious and grade ≥3 TEAEs occurred in 0%-85.7% and 33.3%-100.0% of patients across treatment groups, respectively. All pemigatinib combinations demonstrated steady-state PK comparable to monotherapy. Pharmacodynamic effects in all pemigatinib combinations, except pemi/gem/cis, were consistent with monotherapy. Less inhibition of FGFR2α phosphorylation was observed with this combination. ORRs (95% confidence interval) were 37.5% [8.5% to 75.5% (pemi/gem/cis)], 14.3% [0.4% to 57.9% (pemi/doc)], 0% (pemi/tras), 26.9% [11.6% to 47.8% (pemi/pembro)], and 11.1% [1.4% to 34.7% (pemi/reti)]. All groups had instances of tumor shrinkage. ORRs in assessable patients with FGFR rearrangements and mutations were 50% and 33%, respectively.

CONCLUSIONS:

Pemigatinib combination therapy showed no unexpected toxicities. PK and pharmacodynamics were mostly consistent with pemigatinib monotherapy. Pemi/gem/cis (37.5%) and pemi/pembro (26.9%) had the highest ORR; most responders had FGFR alterations.

2024-05-01·European Urology Oncology

Retifanlimab in Advanced Penile Squamous Cell Carcinoma: The Phase 2 ORPHEUS Study

Article

作者: López-Montero, Laura ; Páez López-Bravo, David ; Climent, Miguel A ; Necchi, Andrea ; Alcalá-López, Daniel ; Sampayo-Cordero, Miguel ; Gómez de Liaño, Alfonso ; Cuéllar-Rivas, Miler Andrés ; Maroto, Pablo ; Giannatempo, Patrizia ; Castellano, Daniel ; García Del Muro, Xavier ; P Valderrama, Begoña ; Mina, Leonardo

BACKGROUND AND OBJECTIVE:

Patients with advanced penile squamous cell carcinoma (PSCC) have poor outcomes and very limited therapeutic options are available. Most PSCC cases have high PD-L1 expression, which is associated with worse prognosis. Immunotherapy targeting PD-L1 could benefit patients with PSCC. Our aim was to evaluate the efficacy and safety of the anti-PD-1 antibody retifanlimab in patients with advanced/metastatic PSCC.

METHODS:

ORPHEUS was a single-arm, multicenter, phase 2 trial in 18 patients with advanced/metastatic PSCC, previously untreated with anti-PD-1/anti-PD-L1 agents. Patients received retifanlimab 500 mg intravenously every 4 wk for up to 2 yr. The primary endpoint was the objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumors v1.1. Secondary endpoints included the clinical benefit rate (CBR), disease control rate, duration of response (DoR), time to response, progression-free survival (PFS), overall survival (OS), maximum tumor shrinkage, and safety. The Wilson method was used for the primary endpoint, and the Clopper-Pearson and Kaplan-Meier methods for secondary endpoints.

KEY FINDINGS AND LIMITATIONS:

Median follow-up was 7.2 mo. The ORR was 16.7% (95% confidence interval [CI] 5.8-39.2); three patients had a partial response. Median DoR was 3.3 mo (range 1.8-8.5). The CBR was 22.2% (95% CI 6.4-47.6%). Median PFS was 2.0 mo (95% CI 1.6-3.3) and median OS was 7.2 mo (95% CI 3.0-9.8). One patient (5.6%) experienced grade 3 treatment-related adverse events (AEs). There were no grade >= 4 treatment-related AEs. The small sample size is the main limitation.

CONCLUSIONS AND CLINICAL IMPLICATIONS:

Single-agent retifanlimab exhibited signals of clinical activity in advanced/metastatic PSCC, with no new safety signals. Further investigation of retifanlimab in this setting is warranted.

PATIENT SUMMARY:

Advanced penile cancer of the squamous cell type is a rare tumor with poor prognosis. The aggressiveness of this cancer is usually associated with high levels of a protein called PD-L1. We investigated whether retifanlimab, an immunotherapy drug against PD-1, has activity against this type of penile cancer. Tumor regression or stabilization occurred in one-third of the patients and the side effects were manageable.

115

项与瑞弗利单抗相关的新闻（医药）

2024-11-26

·GlobeNewswire-Health Care

BriaCell 2024 SABCS® Spotlight Poster to Showcase Positive Overall Survival Data Across All Patient Subtypes in Metastatic Breast Cancer

SABCS® “Spotlight” poster to be presented on Wednesday, December 11, 2024 7:00 AM – 8:30 AM CST highlights positive BriaCell survival and clinical benefit data across all metastatic breast cancer patient subtypes Median overall survival of 13.4 months exceeds historical controls. Phase 2 final median overall survival calculation is pending, as many patients remain alivePotential identification of biomarkers to predict responseFive poster presentations to feature increased presence of cancer fighting CD8+ “killer” T cell in metastatic breast cancer tumors, response in central nervous system (CNS) metastases and additional Bria-IMT™ clinical data from the Phase 2 trial of Bria-IMT™ + immune check point inhibitor in metastatic breast cancer Collaboration with the Medical College of Wisconsin will investigate use of Bria-IMT™ + CPI in any cancer patient with central nervous system (CNS) metastases PHILADELPHIA and VANCOUVER, British Columbia, Nov. 26, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, will be highlighting its positive overall survival and clinical benefit data in metastatic breast cancer (MBC) patients including those with CNS metastasis (not shown on the abstracts) who were treated with the Bria-IMT™ plus immune checkpoint inhibitor (CPI) combination in its “Spotlight” poster presentation session, at the 2024 San Antonio Breast Cancer Symposium® (SABCS®) held at Henry B. Gonzalez Convention Center, San Antonio, TX. “In the Phase 2 study, the Bria-IMT™ combination regimen significantly increased overall survival versus comparable published benchmarks. Additionally, objective response rate and clinical benefit rate data, support the potential benefit of Bria-IMT™ plus CPI in patients with this difficult-to-treat cancer,” stated Saranya Chumsri, MD, Principal Investigator, and Professor of Oncology, Mayo Clinic. “We plan to confirm the impressive clinical data in the BriaCell pivotal Phase 3 study as we continue to explore the use of Bria-IMT™ regimen across all breast cancer subtypes.” “At BriaCell, we are committed to finding therapeutic options for difficult-to-treat metastatic breast cancer patients,” stated Dr. William V. Williams, BriaCell’s President & CEO. “BriaCell’s clinical data demonstrating impressive overall survival in all patient subsets including very difficult to treat patient populations, such as those who have failed prior checkpoint inhibitor and/or antibody-drug conjugate therapy, reinforces our confidence in the potential use of the combination regimen in MBC patients. Additionally, clinical benefit was seen across metastatic breast cancer subtypes including HER2+, HR+/HER2-, and even in triple-negative breast cancer (TNBC) patients. Bria-IMT™ may provide a significant contribution to the lives of patients and their families fighting this incurable disease.” The details about the submitted abstracts are as follows: Abstract Number: SESS-1071 (Selected as Spotlight Poster)Title: Overall survival results of Bria-IMT allogenic whole cell-based cancer vaccineTime: Wednesday, December 11, 2024 7:00 AM – 8:30 AM CSTPresentation ID: PS3-06 Abstract Summary: 54 patients were enrolled with 22 patients in phase 1 and 32 patients in phase 2.11 patients were treated with pembrolizumab and 44 patients with retifanlimab (1 patient received pembrolizumab and later retifanlimab).The Bria-IMT™ combination regimen was well tolerated.The Bria-IMT™ regimen demonstrated promising results across all subtypes of breast cancer with favorable safety profiles.Patients receiving the pivotal Phase 3 Bria-IMT™ combination regimen (n=37) showed significantly higher median overall survival (OS) (13.4), an objective response rate (ORR) of 9.5% and a clinical benefit rate (CBR) of 55%.Final median overall survival calculation for the Phase 2 study is pending, as many patients remain alive.Among 36 patients with post-dose cancer-associated circulating tumor cell (CTC) data, patients with post-dose CTC count < 5 had a significantly better OS compared with a CTC count > 5 (13.4 vs. 5.5 months, P 0.01).Patients with positive delayed type hypersensitivity (DTH), an inflammatory marker to measure the response to Bria-IMT™ immunization, had significantly better OS. “Our clinical findings support the use of the current Phase 3 formulation,” noted Giuseppe Del Priore, MD, MPH, BriaCell’s Chief Medical Officer. “We plan to confirm the potential use of key biomarkers to predict patient clinical outcomes in the Bria-IMT™ plus CPI ongoing pivotal Phase 3 study (NCT06072612) in metastatic breast cancer.” Abstract Number: SESS-1431Title: Identification of antigenic determinants in SV-BR-1 derived cellular breast cancer vaccinesTime: Wednesday, December 11, 2024 5:30 – 7:00 PM CSTPresentation ID: P2-06-02 Abstract Number: SESS-2217Title: PD-L1 upregulation in circulating tumor associated cells predicts for clinical outcomes in a phase I/II clinical trial using SV-BR-1-GM vaccine with the checkpoint inhibitor retifanlimab in metastatic breast cancer patients, an interim analysisTime: Wednesday, December 11, 2024 12:00 – 2:00 PM CSTPresentation ID: P1-01-17 Abstract Number: SESS-1068Abstract Title: ASTRO-VAC CNS: Bria-IMT in the management of tumor agnostic metastatic CNS lesionsTime: Wednesday, December 11, 2024 5:30 – 7:00 PM CSTPresentation ID: P2-10-24 Abstract Number: SESS-1069Title: Bria-IMT CD8+ tumor infiltrating lymphocytes turn “Cold” tumor “Hot” in metastatic breast cancerTime: Friday, December 13, 2024 12:00 PM – 2:00 PM CSTPresentation ID: P5-10-12 Following presentations, the posters can be viewed at the following: https://briacell.com/scientific-publications/. About BriaCell Therapeutics Corp. BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/. Safe Harbor This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about BriaCell’s potential use of key biomarkers to predict patient clinical outcomes in the Bria-IMT™ plus CPI ongoing pivotal Phase 3 study; BriaCell’s potential use of the combination regimen in MBC patients; BriaCell conducting a poster presentation at the 2024 San Antonio Breast Cancer Symposium®, and the contents of such presentation; the potential benefit of Bria-IMT™ plus CPI in cancer patients; BriaCell’s plans to confirm the clinical data in their pivotal Phase 3 study; BriaCell’s Phase 3 study exploring the use of the Bria-IMT™ regimen across all breast cancer subtypes; and the Bria-IMT™ regimen having the potential to provide a significant contribution to the lives of cancer patients are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements, such as those are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company’s most recent Management’s Discussion and Analysis, under the heading “Risk Factors” in the Company’s most recent Annual Information Form, and under “Risks and Uncertainties” in the Company’s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law. Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release. Contact Information Company Contact:William V. Williams, MDPresident & CEO1-888-485-6340info@briacell.com Media Relations:Jules AbrahamCORE IRjulesa@coreir.com Investor Relations Contact:CORE IRinvestors@briacell.com

临床结果临床2期免疫疗法临床3期疫苗

2024-11-25

·Business Wire

Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting

WILMINGTON, Del.--( BUSINESS WIRE )--Incyte (Nasdaq: INCY) today announced that the Company will present new data from across its oncology portfolio at the 2024 American Society of Hematology (ASH) Annual Meeting in San Diego. “These data illustrate our innovative approach that aims to identify new and best-in-class treatments for patients with a range of cancers,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “At ASH, we’re presenting comprehensive data from our Phase 3 inMIND trial in relapsed or refractory follicular lymphoma. This late-breaking presentation provides valuable insights into the potential role of tafasitamab in improving outcomes for FL patients who currently face limited effective treatment options.” Details on key abstracts accepted for presentation include: ASH Abstracts Late-Breaking Oral Presentation Tafasitamab Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND) Session: Late-Breaking Abstracts Session. Publication Number: LBA-1. December 10, 10:30 a.m. ET (7:30 a.m. PT). Oral Presentations Axatilimab Dynamics of Overall and Organ-Specific Responses to Axatilimab in Chronic Graft-Versus-Host Disease: Analysis from the AGAVE-201 Study Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Predicting and Treating Acute and Chronic GVHD. Publication Number: 98. December 7, 12:45 p.m. ET (9:45 a.m. PT). INCB057643 Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitor INCB057643 in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study Session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Advancing Treatment Paradigms in Myeloproliferative Neoplasms and Mastocytosis. Publication Number: 658. December 8, 8:15 p.m. ET (5:15 p.m. PT). Poster Presentations Ruxolitinib (Myeloproliferative Neoplasms [MPN]) Clinical and Molecular Characterization of Disease Progression in Patients (Pts) with Low-Risk Myelofibrosis (MF) Enrolled in the MOST Study Poster Session: 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster II. Publication Number: 3136. December 8, 9:00 p.m. – 11:00 p.m. ET. (6:00 p.m. – 8:00 p.m. PT). Molecular Predictors of Disease Progression to Myelofibrosis (MF) in Patients (Pts) with Polycythemia Vera (PV) Enrolled in REVEAL Poster Session: 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster II. Publication Number: 3145. December 8, 9:00 p.m. – 11:00 p.m. ET. (6:00 p.m. – 8:00 p.m. PT). Real-World Treatment Patterns and Blood Count Control in Patients with Polycythemia Vera Who Switched From Hydroxyurea to Ruxolitinib Poster Session: 908. Outcomes Research: Myeloid Malignancies: Poster II. Publication Number: 3813. December 8, 9:00 p.m. – 11:00 p.m. ET. (6:00 p.m. – 8:00 p.m. PT). Clinical Outcomes in Patients with Myelofibrosis Treated with Ruxolitinib and Anemia-Supporting Medications Poster Session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III. Publication Number: 4546. December 9, 9:00 p.m. – 11:00 p.m. ET. (6:00 p.m. – 8:00 p.m. PT). Ruxolitinib (Graft-versus-host Disease [GVHD]) Real-World Ruxolitinib and Corticosteroid Treatment Patterns in Patients with Chronic Graft-Versus-Host Disease in the United States Poster Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster III. Publication Number: 4900. December 9, 9:00 p.m. – 11:00 p.m. ET. (6:00 p.m. – 8:00 p.m. PT). Tafasitamab Real-World Effectiveness of Tafasitamab (Tafa) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the United States Poster Session: 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster I. Publication Number: 2375. December 7, 8:30 p.m. – 10:30 p.m. ET (5:30 p.m. – 7:30 p.m. PT). Maintenance of CD19 Expression After Tafasitamab Treatment in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) From Clinical Trial and Real-World Settings Poster Session: 622. Lymphomas: Translational – Non-Genetic: Poster II. Publication Number: 2991. December 8, 9:00 p.m. – 11:00 p.m. ET. (6:00 p.m. – 8:00 p.m. PT). Axatilimab Axatilimab Abrogates Inflammatory Cytokines and Chemokines and Interrupts the Differentiation of Monocytes to Macrophages, a Pathogenic Driver of Inflammation and Fibrosis in cGVHD Poster Session: 201. Granulocytes, Monocytes, and Macrophages: Poster I. Publication Number: 1147. December 7, 8:30 p.m. – 10:30 p.m. ET (5:30 p.m. – 7:30 p.m. PT). Exposure-Response Relationships for Axatilimab, a Humanized Monoclonal Antibody Targeting CSF-1R, in Patients with Chronic Graft-Versus-Host Disease Poster Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster I. Publication Number: 2140. December 7, 8:30 p.m. – 10:30 p.m. ET (5:30 p.m. – 7:30 p.m. PT). Real-World Patient Characteristics and Treatment Patterns in Patients with Chronic Graft-Versus-Host Disease Receiving Belumosudil in the United States Poster Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster II. Publication Number: 3522. December 8, 9:00 p.m. – 11:00 p.m. ET. (6:00 p.m. – 8:00 p.m. PT). Ponatinib The Impact of Ponatinib on Pregnancy Outcomes Poster Session: 908. Outcomes Research: Myeloid Malignancies: Poster I. Publication Number: 2435. December 7, 8:30 p.m. – 10:30 p.m. ET (5:30 p.m. – 7:30 p.m. PT). Long-Term Safety and Effectiveness of Ponatinib Treatment in Patients with TKI Intolerance: Subgroup Analysis of the Observational Study of Ponatinib Treatment in Patients with CML in Italy (OITI) Poster Session: 908. Outcomes Research: Myeloid Malignancies: Poster I. Publication Number: 2427. December 7, 8:30 p.m. – 10:30 p.m. ET (5:30 p.m. – 7:30 p.m. PT). Ponatinib Safety Profile: An Analysis of 10-Years of Real-World Experience Poster Session: 908. Outcomes Research: Myeloid Malignancies: Poster II. Publication Number: 3816. December 8, 9:00 p.m. – 11:00 p.m. ET. (6:00 p.m. – 8:00 p.m. PT). INCB057643 Machine Learning in Predicting Longitudinal Platelet Counts: Applications in Dose Optimization Poster Session: 803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Poster III. Publication Number: 4985. December 9, 9:00 p.m. – 11:00 p.m. ET. (6:00 p.m. – 8:00 p.m. PT). More information regarding the 2024 ASH Annual Meeting can be found on their website: https://www.hematology.org/meetings/annual-meeting/schedule-and-program . All sessions will be broadcast virtually, and access to the meeting’s virtual platform is included with registration. Conference Call and Webcast Incyte will hold a conference call and webcast on Thursday, December 12, 2024, from 4:00-5:00 p.m. ET, to discuss key data presentations at ASH, including data from the Phase 3 inMIND study presented during the late breaking session and its BET inhibitor program. To access the conference call, please dial 877-407-3042 for domestic callers or 201-389-0864 for international callers. When prompted, provide the conference identification number, 13750244. If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the United States is 877-660-6853 and the dial-in number for international callers is 201-612-7415. To access the replay, you will need the conference identification number, 13750244. The live webcast with slides can be accessed at Investor.Incyte.com and will be available for replay for ninety days. About Jakafi ® (ruxolitinib) Jakafi ® (ruxolitinib) is a JAK1/JAK2 inhibitor approved by the U.S. FDA for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea; intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF in adults; steroid-refractory acute GVHD in adult and pediatric patients 12 years and older; and chronic GVHD after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older. Jakafi is a registered trademark of Incyte. About Monjuvi ® (tafasitamab-cxix) Monjuvi ® (tafasitamab-cxix) is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. Tafasitamab incorporates an XmAb ® engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cellular Phagocytosis (ADCP). MorphoSys and Incyte entered into: (a) in January 2020, a collaboration and licensing agreement to develop and commercialize tafasitamab globally; and (b) in February 2024, an agreement whereby Incyte obtained exclusive rights to develop and commercialize tafasitamab globally. In the United States, Monjuvi ® (tafasitamab-cxix) received accelerated approval by the U.S. Food and Drug Administration in combination with lenalidomide for the treatment of adult patients with relapsed or refractory DLBCL not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT). In Europe, Minjuvi ® (tafasitamab) received conditional Marketing Authorization from the European Medicines Agency in combination with lenalidomide, followed by Minjuvi monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT). XmAb ® is a registered trademark of Xencor, Inc. Monjuvi, Minjuvi, the Minjuvi and Monjuvi logos and the “triangle” design are registered trademarks of Incyte. About Zynyz ® (retifanlimab-dlwr) Zynyz ® (retifanlimab-dlwr), is an intravenous PD-1 inhibitor indicated in the U.S. for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. Zynyz is marketed by Incyte in the U.S. In 2017, Incyte entered into an exclusive collaboration and license agreement with MacroGenics, Inc. for global rights to retifanlimab. Zynyz is a registered trademark of Incyte. About Pemazyre ® (pemigatinib) Pemazyre ® (pemigatinib) is a kinase inhibitor indicated in the United States for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test*. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). Pemazyre is also the first targeted treatment approved for use in the United States for treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement. In Japan, Pemazyre is approved for the treatment of patients with unresectable biliary tract cancer (BTC) with a fibroblast growth factor receptor 2 (FGFR2) fusion gene, worsening after cancer chemotherapy. In Europe, Pemazyre is approved for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy. Pemazyre is a potent, selective, oral inhibitor of FGFR isoforms 1, 2 and 3 which, in preclinical studies, has demonstrated selective pharmacologic activity against cancer cells with FGFR alterations. Pemazyre is marketed by Incyte in the United States, Europe and Japan. Pemazyre and the Pemazyre logo are registered trademarks of Incyte. * Pemazyre ® (pemigatinib) [Package Insert]. Wilmington, DE: Incyte; 2020. About Niktimvo™ (axatilimab-csfr) Niktimvo™ (axatilimab-csfr) is a first-in-class anti-CSF-1R antibody approved for use in the U.S. for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg (88.2 lbs). In 2016, Syndax licensed exclusive worldwide rights to develop and commercialize Niktimvo from UCB. In September 2021, Syndax and Incyte entered into an exclusive worldwide co-development and co-commercialization license agreement for Niktimvo in cGVHD and any future indications. Axatilimab is being studied in frontline combination trials in chronic GVHD – a Phase 2 combination trial with ruxolitinib (NCT06388564) and a Phase 3 combination trial with steroids are expected to initiate by year end. Axatilimab is also being studied in an ongoing Phase 2 trial in patients with idiopathic pulmonary fibrosis (NCT06132256). Niktimvo is a trademark of Incyte. All other trademarks are the property of their respective owners. Niktimvo (axatilimab-csfr) is licensed from Syndax. About Iclusig ® (ponatinib) tablets Iclusig ® (ponatinib) targets not only native BCR-ABL but also its isoforms that carry mutations that confer resistance to treatment, including the T315I mutation, which has been associated with resistance to other approved TKIs. In the EU, Iclusig is approved for the treatment of adult patients with chronic phase, accelerated phase or blast phase chronic myeloid leukemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation, or the treatment of adult patients with Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation. Click here to view the Iclusig EU Summary of Medicinal Product Characteristics. Incyte has an exclusive license from Takeda Pharmaceuticals International AG to commercialize ponatinib in the European Union and 29 other countries, including Switzerland, UK, Norway, Turkey, Israel and Russia. Iclusig is marketed in the U.S. by Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. About Incyte A global biopharmaceutical company on a mission to Solve On. , Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia. For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn , X , Instagram , Facebook , YouTube . Incyte Forward-Looking Statements Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation of data from Incyte’s clinical development pipeline, the potential presented by that pipeline, whether or when any development compounds or combinations will be approved or commercially available for use in humans anywhere in the world outside of the already approved indications in specific regions and Incyte’s goal of improving the lives of patients, contain predictions, estimates, and other forward-looking statements. These forward-looking statements are based on our current expectations and are subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials and the ability to enroll subjects in accordance with planned schedules; determinations made by the FDA and regulatory agencies outside of the United States; the efficacy or safety of our products; the acceptance of our products in the marketplace; market competition; unexpected variations in the demand for our products and the products of our collaboration partners; the effects of announced or unexpected price regulation or limitations on reimbursement or coverage for our products; sales, marketing, manufacturing, and distribution requirements, including our ability to successfully commercialize and build commercial infrastructure for newly approved products and any additional new products that become approved; and other risks detailed from time to time in our reports filed with the U.S. Securities and Exchange Commission, including our annual report on Form 10-K and our quarterly report on Form 10-Q for the quarter ended September 30, 2024. We disclaim any intent or obligation to update these forward-looking statements.

临床3期上市批准引进/卖出ASH会议临床结果

2024-11-04

·佰傲谷BioValley

一路崩坏的MacroGenics，CEO也要辞职了

MacroGenics局势崩坏至此？该公司联合创始人、总裁兼首席执行官Scott Koenig正在计划离职。日前，MacroGenics宣布了领导层交接，Scott Koenig计划在明年初辞去总裁兼首席执行官的职位。不过Scott Koenig将继续作为MacroGenics的顾问和股东。受到该消息的影响，MacroGenics的股价反而出现小幅度上涨。管线一款接一款失败 MacroGenics成立于2000年，是老牌抗体公司。基于其DART 、TRIDENT等技术平台，公司与赛诺菲、吉利德、Incyte、再鼎医药、天境生物等公司建立了重要的合作关系，单抗和双抗管线大多进行了授权转让。不过平台技术的安全性验证遭遇不小挑战。特别是公司重点押注的B7H3靶点，单抗，双抗产品皆这折戟于不良事件。 2019年1月，FDA叫停了CD3/B7H3双抗MGD009针对B7H3阳性实体瘤的临床I期试验，因为该临床出现了肝脏不良事件。目前公司官网已无该管线信息。 2022年7月，B7H3单抗MGA271一项治疗复发难治性头颈鳞癌的II期临床试验被MacroGenic宣布停止，原因是该临床出现了11.3%的死亡事件（62名患者中7人死亡），可能与出血事件有关。 2024年8月，B7H3 ADC药物Vobramitamab Duocarmazine（MGC-018）的II期临床TAMARACK被MacroGenic宣布停止，原因是TAMARACK试验中发生了5例患者死亡事件。不过该B7H3 ADC联合lorigerlimab（PD-1×CTLA-4 DART分子）的1/2期剂量递增研究继续患者招募，并计划于今年晚些时候进行剂量扩展研究。延伸阅读：B7H3 ADC毒性累积此外，2024年3月，艾伯维终止了与MacroGenics在ADAM9 ADC上的合作，因为临床I期数据未达预期。目前，MacroGenics重点管线有三款，分别是处于早期临床的B7H3 ADC MGC026和PD-1×CTLA-4 DART分子lorigerlimab，以及临床前的ADAM9 ADC MGC028。管线一款接着一款的失败，也就算了，毕竟管线开发失败乃是兵家常事。可难受的，还有缺钱的窘境，以及管线持续烧钱的现况。缺钱的窘境 MacroGenics共开发了三款商业化产品，分别是MARGENZA、ZYNYZ、TZIELD。 ZYNYZ和TZIELD早早的被授权出去，并为MacroGenics带来了不菲的收入，但是架不住MacroGenics花钱快啊。根据MacroGenics发布的2024年第二季度财报，公司季度净亏损5570万美元。截止第二季度，现金流只剩下1.4亿美元的MacroGenics，也有些着急了。打包出售MARGENZA MARGENZA（Margetuximab）是一款HER2单抗，于2020年获FDA批准，用于治疗转移性HER2+乳腺癌患者。值得注意的是，再鼎曾在2018年引进了Margetuximab，Margetuximab于2023年9月获得中国药监局批准，不过由于再鼎并未启动商业化运营，MacroGenics无法拿到其里程碑款项。今年早些时候，再鼎终止了与MacroGenics关于Margetuximab合作，协议已于2024年5月14日生效。 MARGENZA在MacroGenics自己商业化运营下，销售情况惨淡。根据MacroGenics发布的2024年第二季度财报，产品季度净销售额约为525万美元。如果产品不赚钱，就及时卖掉回血。 2024年10月，MacroGenics将MARGENZA打包出售给TerSera Therapeutics LLC。根据协议条款，TerSera将以4000万美元的前期付款+3500万美元的里程碑付款获得MARGENZA的全球权利。相较于MARGENZA的营收，说不上是卖了一个好价钱，但起码让MacroGenics回笼了一笔资金。指望Incyte的里程碑打款 ZYNYZ（retifanlimab）是一款PD-1单抗，于2017年授权给Incyte。ZYNYZ于2023年3月23日首次获得FDA批准，用于治疗转移性或复发局部晚期默克尔细胞癌（MCC）成人患者。根据Incyte公司财报，ZYNYZ在今年前六个月的销售额仅为100万美元。延伸阅读：FDA加速批准PD-1单抗一线治疗默克尔细胞癌 MacroGenics与Incyte于2024年7月达成协议，宣布已经实现与retifanlimab开发进度相关的1亿美元里程碑。此外，MacroGenics还有资格从Incyte获得高达 2.1亿美元的剩余开发和监管里程碑，以及高达3.3亿美元的潜在商业里程碑。以及，MacroGenics从Incyte获得该产品全球净销售额的15%至24%的分层特许权使用费。 TZIELD早就被卖了 TZIELD（teplizumab）是一款CD3单抗，于2018年授权给了Provention Bio。TZIELD于2022年11月获得FDA批准，用于预防/延缓1型糖尿病。 2023年3月，赛诺菲以约29亿美元收购了Provention Bio，获得了TZIELD。延伸阅读：1型糖尿病百年首个革命性疗法，CD3单抗终获批 MacroGenics原本还拥有TZIELD的专利权，能够获得TZIELD全球净销售额的个位数专利使用费。但是由于MacroGenics等不及这笔权益慢慢变现，直接就在2024年3月将Tzield的专利权以1亿美元的预付款出售给了药物专利权收购公司DRI Healthcare Trust。小结 MacroGenics共开发了三款商业化产品，但三款产品现在都不属于MacroGenics了。作为技术公司，不善商业操作，将管线授权出去也是一种优选择。但是MacroGenics孵化了三款商业化产品，手握专利权，按理来说，应该是躺下收钱了。参考资料： 1.https://ir.macrogenics.com/news-releases/news-release-details/macrogenics-announces-leadership-transition 2.https://ir.macrogenics.com/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-second-quarter 本周好文推荐如需转载请联系佰傲谷并在醒目位置注明出处 · · · · · · · ·

财报抗体药物偶联物临床2期临床1期引进/卖出

100 项与瑞弗利单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11827	-	-	DB15766

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
转移性Merkel细胞癌	美国	Incyte Corp.	2023-03-22

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
子宫内膜癌	临床3期	中国	再鼎医药（上海）有限公司	2021-09-20
肛管鳞状细胞癌	临床3期	美国	Incyte Corp.	2021-01-12
肛管鳞状细胞癌	临床3期	日本	Incyte Corp.	2021-01-12
肛管鳞状细胞癌	临床3期	澳大利亚	Incyte Corp.	2021-01-12
肛管鳞状细胞癌	临床3期	比利时	Incyte Corp.	2021-01-12
肛管鳞状细胞癌	临床3期	丹麦	Incyte Corp.	2021-01-12
肛管鳞状细胞癌	临床3期	法国	Incyte Corp.	2021-01-12
肛管鳞状细胞癌	临床3期	德国	Incyte Corp.	2021-01-12
肛管鳞状细胞癌	临床3期	意大利	Incyte Corp.	2021-01-12
肛管鳞状细胞癌	临床3期	挪威	Incyte Corp.	2021-01-12

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03328026 (SABCS2024 \| GlobeNewswire) 人工标引	临床1/2期	转移性乳腺癌	54	Bria-IMT regimen with pembrolizumab/retifanlimab	淵簾蓋衊鹹鹽網鹽蓋獵(遞壓鹹範鹽願壓膚鏇願) = 範夢製鑰餘齋夢憲鬱艱範齋鹹蓋齋襯範襯廠衊 (壓夢構鏇憲壓構積鹹願 )	积极	2024-12-11
				Bria-IMT regimen with pembrolizumab/retifanlimab (without IFN incubation; phase 3 formulation)	淵簾蓋衊鹹鹽網鹽蓋獵(遞壓鹹範鹽願壓膚鏇願) = 壓衊繭簾鬱鹹簾膚廠遞範齋鹹蓋齋襯範襯廠衊 (壓夢構鏇憲壓構積鹹願 ) 更多
NCT04438824 (ESMO2024) 人工标引	临床2期	去分化脂肪肉瘤	28	Palbociclibretifanlimab	(壓艱顧鬱壓選製糧壓製) = 獵遞膚獵製觸衊繭製製鑰窪鬱範繭積廠糧窪願 (築壓顧窪窪鬱衊艱選廠, 4.7 ~ 33.6) 更多	积极	2024-09-13
NCT03328026 (ASCO2024) 人工标引	临床1/2期	转移性乳腺癌 \| 晚期乳腺癌 CAMLs \| CTCs	54	SV-BR-1-GMegimen with oriretifanlimabce	(蓋範獵網蓋衊餘窪獵憲) = 構積壓蓋觸築鏇襯鹹獵廠窪願壓襯糧製繭積網 (願淵構鑰積廠襯觸鹹壓 ) 更多	积极	2024-05-24
NCT04634825 (CTgov)	临床2期	转移性头颈部鳞状细胞癌	62	Enoblituzumab+Retifanlimab (Retifanlimab Cohort)	窪繭構壓蓋鑰膚築顧餘(膚構鏇廠壓鹹窪鬱憲遞) = 願簾鑰構顧膚鏇鹹範簾淵夢鏇廠遞廠艱觸醖獵 (簾鹹憲壓顧窪獵蓋製觸, 築積醖窪鹹壓選廠淵簾 ~ 簾構觸積壓襯夢齋願選) 更多	-	2023-12-20
				Enoblituzumab+Tebotelimab (Tebotelimab Cohort)	淵鹽願範築襯鏇鬱鹹繭(範鑰鹽衊艱網蓋鏇衊淵) = 淵廠膚繭襯醖壓範構蓋構衊鏇醖範衊蓋餘壓簾 (獵鹽網壓網遞窪簾鬱鑰, 簾遞窪餘蓋衊願鹹襯範 ~ 積範窪構遞鹹鹽憲窪衊) 更多
NCT03059823 (POD1UM-101, ESMO2023) 人工标引	临床1期	错配修复缺陷子宫内膜癌 \| MSI-H 子宫内膜癌 MSI-High \| Deficient DNA Mismatch Repair (dMMR)	76	Retifanlimab 500 mg	鬱憲範範遞窪窪膚築簾(願鏇構襯顧蓋網獵簾構) = 觸製夢衊鹹鑰衊鏇鏇觸衊範鏇鹽齋憲繭壓窪製 (網鹹廠糧膚壓醖簾壓鏇, 32 ~ 55)	积极	2023-10-22
NCT04231981 (ORPHEUS, ASCO2023) 人工标引	临床2期	阴茎鳞状细胞癌	18	Retifanlimab	鹹築遞製糧膚願膚獵獵(積簾壓鬱糧夢選壓選醖) = 網鹽窪壓獵糧願蓋觸鬱廠鹽鹽積獵築夢簾餘壓 (醖願簾網鏇願觸簾願憲, 5.8 ~ 39.2) 更多	积极	2023-05-26
NCT04370704 (ASCO2023) 人工标引	临床1/2期	HR阳性/HER2低表达实体瘤	21	INCAGN02385 350 mg+INCAGN02390 400 mg	選艱衊選選鏇窪鬱鏇鬱(範選顧範構鏇獵範簾網) = occurred in 1 pt in part 1 (grade [G] 3 vasculitis) and 1 pt in part 2 (G3 myocarditis and pericardial effusion) 鏇築鑰製艱簾鬱獵壓糧 (鏇鑰襯齋遞淵淵鹹範繭 ) 更多	积极	2023-05-26
				retifanlimab 500 mg+INCAGN02385 350 mg+INCAGN02390 400 mg
NCT04225039 (ASCO2023) 人工标引	临床2期	复发性胶质母细胞瘤	32	INCAGN01876+Retifanlimab+FSRT (single-arm, primary efficacy cohort)	窪遞壓遞範襯簾積積鏇(膚憲廠鏇願窪繭網餘製) = 範鹽壓衊廠鹹遞願夢範醖鏇製顧艱齋襯網願遞 (憲鑰膚獵顧膚鬱顧壓蓋, 2.1 ~ 6.2) 更多	不佳	2023-05-26
				INCAGN01876+Retifanlimab+FSRT (two-arm neoadjuvant window-of-opportunity cohort)	窪遞壓遞範襯簾積積鏇(膚憲廠鏇願窪繭網餘製) = 積築衊廠範餘範簾衊膚醖鏇製顧艱齋襯網願遞 (憲鑰膚獵顧膚鬱顧壓蓋 ) 更多
NCT04577014 (ASCO2023) 人工标引	临床2期	局部晚期软组织肉瘤一线	43	Retifanlimab+gemcitabine+docetaxel	鹽衊膚齋範網蓋夢夢糧(製簾觸構鹽衊鏇遞築範) = 製艱夢齋範壓鏇顧夢繭網淵選製鬱選衊觸廠簾 (餘積淵簾簾齋鬱願餘積 ) 更多	积极	2023-05-26
NCT03599713 (POD1UM-201, CTgov)	临床2期	转移性Merkel细胞癌	107	retifanlimab (Chemotherapy: Naïve)	願襯鹽鬱衊繭築膚選遞(憲襯繭積願蓋願廠壓鑰) = 糧鹽壓餘餘選餘簾壓築簾壓鹽顧淵憲獵醖製夢 (積鏇簾膚衊糧憲憲築製, 醖艱醖膚艱願簾鹽築鏇 ~ 憲鏇遞鹽蓋簾簾積觸鏇) 更多	-	2023-05-03
				retifanlimab (Chemotherapy: Refractory)	壓鏇鏇積鑰窪醖顧範膚(繭鹽淵憲壓簾築糧壓鹹) = 齋構顧夢繭簾齋蓋範廠壓醖醖齋構觸窪鹽餘齋 (糧醖壓醖鹽選鹽簾選餘, 顧鹹膚繭築淵觸糧繭夢 ~ 積鬱鬱夢鹽蓋選夢艱廠) 更多